Free Trial

Extendicare (TSE:EXE) Sets New 1-Year High - Should You Buy?

Extendicare logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Extendicare hit a new 52‑week high of C$35.62 and last traded at C$34.34 on volume of 293,212 shares.
  • Analysts have mostly upgraded the stock—one Strong Buy and five Buy ratings—with a MarketBeat consensus of Buy and a consensus target of C$29.38, which is below the current share price despite several raised targets up to C$34.50.
  • Key fundamentals: market cap C$3.33B, PE 31.69, debt-to-equity 91.85, ROE 47.65%; reported Q EPS C$0.42 on C$465.22M revenue, and a recently declared monthly dividend of $0.0441 (annual yield ~1.5%, payout ratio ~44.9%).
  • MarketBeat previews top five stocks to own in June.

Extendicare Inc. (TSE:EXE - Get Free Report)'s share price hit a new 52-week high on Friday . The company traded as high as C$35.62 and last traded at C$34.34, with a volume of 293212 shares changing hands. The stock had previously closed at C$30.20.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on EXE shares. TD Securities raised shares of Extendicare from a "hold" rating to a "buy" rating and raised their price target for the company from C$19.00 to C$32.00 in a report on Monday, April 6th. Canadian Imperial Bank of Commerce lifted their price target on shares of Extendicare from C$22.00 to C$32.00 in a research note on Thursday, April 2nd. BMO Capital Markets lifted their target price on shares of Extendicare from C$24.00 to C$30.00 in a report on Monday, March 2nd. Desjardins set a C$34.50 price objective on shares of Extendicare and gave the stock a "buy" rating in a research report on Wednesday, April 22nd. Finally, National Bank Financial upped their price objective on shares of Extendicare from C$24.50 to C$29.00 and gave the company an "outperform" rating in a research note on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of C$29.38.

Read Our Latest Analysis on Extendicare

Extendicare Price Performance

The business's fifty day moving average is C$27.61 and its 200-day moving average is C$23.41. The company has a debt-to-equity ratio of 91.85, a current ratio of 1.37 and a quick ratio of 0.98. The firm has a market cap of C$3.33 billion, a PE ratio of 31.69 and a beta of 1.27.

Extendicare (TSE:EXE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported C$0.42 earnings per share (EPS) for the quarter. The business had revenue of C$465.22 million during the quarter. Extendicare had a net margin of 5.82% and a return on equity of 47.65%. On average, research analysts predict that Extendicare Inc. will post 0.6134729 earnings per share for the current fiscal year.

Extendicare Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Friday, May 15th. Investors of record on Friday, May 15th will be paid a dividend of $0.0441 per share. The ex-dividend date of this dividend is Thursday, April 30th. This represents a c) annualized dividend and a yield of 1.5%. Extendicare's payout ratio is currently 44.92%.

Extendicare Company Profile

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines